Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE) Stock Competitors & Peer Comparison
See ZYNE's competitors and their performance on the NASDAQ and across the wider stock market.
Peer Comparison Table: Drug Manufacturers - Specialty & Generic Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for ZYNE and its NASDAQ peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| ZYNE | $1.30 | +2.36% | 70.1M | -1.65 | -$0.79 | N/A |
| TAK | $17.42 | -0.37% | 55.4B | 12.52 | $1.39 | +3.62% |
| HLN | $9.79 | -1.51% | 43.2B | 18.28 | $0.54 | +1.80% |
| TEVA | $37.04 | +1.54% | 42.8B | 12.54 | $2.93 | N/A |
| VTRS | $16.25 | -0.16% | 18.7B | 6.39 | $2.52 | +2.98% |
| ITCI | $131.87 | +0.00% | 14B | -180.64 | -$0.73 | N/A |
| CTLT | $63.48 | +0.00% | 11.5B | -27.84 | -$2.28 | N/A |
| ELAN | $22.60 | -0.59% | 11.1B | 20.91 | $1.06 | N/A |
| RDY | $12.42 | -0.24% | 10.3B | 20.30 | $0.61 | +0.67% |
| LNTH | $100.90 | +0.22% | 6.6B | 16.93 | $5.95 | N/A |
Stock Comparison
Takeda Pharmaceutical Company Limited (NYSE: TAK)
ZYNE vs TAK Comparison August 2026
Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZYNE stands at 70.1M. In comparison, TAK has a market cap of 55.4B. Regarding current trading prices, ZYNE is priced at $1.30 on the NASDAQ, while TAK trades at $17.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZYNE currently has a P/E ratio of -1.65, whereas TAK's P/E ratio is 12.52. In terms of profitability, ZYNE's ROE is -0.59%, compared to TAK's ROE of +0.02%. Regarding short-term risk, ZYNE is more volatile compared to TAK. This indicates higher risk in terms of short-term price fluctuations for ZYNE.Check TAK's competition here
Haleon plc (NYSE: HLN)
ZYNE vs HLN Comparison August 2026
Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZYNE stands at 70.1M. In comparison, HLN has a market cap of 43.2B. Regarding current trading prices, ZYNE is priced at $1.30 on the NASDAQ, while HLN trades at $9.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZYNE currently has a P/E ratio of -1.65, whereas HLN's P/E ratio is 18.28. In terms of profitability, ZYNE's ROE is -0.59%, compared to HLN's ROE of +0.17%. Regarding short-term risk, ZYNE is more volatile compared to HLN. This indicates higher risk in terms of short-term price fluctuations for ZYNE.Check HLN's competition here
Teva Pharmaceutical Industries Limited (NYSE: TEVA)
ZYNE vs TEVA Comparison August 2026
Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZYNE stands at 70.1M. In comparison, TEVA has a market cap of 42.8B. Regarding current trading prices, ZYNE is priced at $1.30 on the NASDAQ, while TEVA trades at $37.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZYNE currently has a P/E ratio of -1.65, whereas TEVA's P/E ratio is 12.54. In terms of profitability, ZYNE's ROE is -0.59%, compared to TEVA's ROE of +0.09%. Regarding short-term risk, ZYNE is more volatile compared to TEVA. This indicates higher risk in terms of short-term price fluctuations for ZYNE.Check TEVA's competition here
Viatris Inc. (NASDAQ: VTRS)
ZYNE vs VTRS Comparison August 2026
Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZYNE stands at 70.1M. In comparison, VTRS has a market cap of 18.7B. Regarding current trading prices, ZYNE is priced at $1.30 on the NASDAQ, while VTRS trades at $16.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZYNE currently has a P/E ratio of -1.65, whereas VTRS's P/E ratio is 6.39. In terms of profitability, ZYNE's ROE is -0.59%, compared to VTRS's ROE of -0.03%. Regarding short-term risk, ZYNE is more volatile compared to VTRS. This indicates higher risk in terms of short-term price fluctuations for ZYNE.Check VTRS's competition here
Intra-Cellular Therapies, Inc. (NASDAQ: ITCI)
ZYNE vs ITCI Comparison August 2026
Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZYNE stands at 70.1M. In comparison, ITCI has a market cap of 14B. Regarding current trading prices, ZYNE is priced at $1.30 on the NASDAQ, while ITCI trades at $131.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZYNE currently has a P/E ratio of -1.65, whereas ITCI's P/E ratio is -180.64. In terms of profitability, ZYNE's ROE is -0.59%, compared to ITCI's ROE of -0.09%. Regarding short-term risk, ZYNE is more volatile compared to ITCI. This indicates higher risk in terms of short-term price fluctuations for ZYNE.Check ITCI's competition here
Catalent, Inc. (NYSE: CTLT)
ZYNE vs CTLT Comparison August 2026
Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZYNE stands at 70.1M. In comparison, CTLT has a market cap of 11.5B. Regarding current trading prices, ZYNE is priced at $1.30 on the NASDAQ, while CTLT trades at $63.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZYNE currently has a P/E ratio of -1.65, whereas CTLT's P/E ratio is -27.84. In terms of profitability, ZYNE's ROE is -0.59%, compared to CTLT's ROE of -0.25%. Regarding short-term risk, ZYNE is more volatile compared to CTLT. This indicates higher risk in terms of short-term price fluctuations for ZYNE.Check CTLT's competition here
Elanco Animal Health Incorporated (NYSE: ELAN)
ZYNE vs ELAN Comparison August 2026
Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZYNE stands at 70.1M. In comparison, ELAN has a market cap of 11.1B. Regarding current trading prices, ZYNE is priced at $1.30 on the NASDAQ, while ELAN trades at $22.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZYNE currently has a P/E ratio of -1.65, whereas ELAN's P/E ratio is 20.91. In terms of profitability, ZYNE's ROE is -0.59%, compared to ELAN's ROE of -0.03%. Regarding short-term risk, ZYNE is more volatile compared to ELAN. This indicates higher risk in terms of short-term price fluctuations for ZYNE.Check ELAN's competition here
Dr. Reddy's Laboratories Limited (NYSE: RDY)
ZYNE vs RDY Comparison August 2026
Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZYNE stands at 70.1M. In comparison, RDY has a market cap of 10.3B. Regarding current trading prices, ZYNE is priced at $1.30 on the NASDAQ, while RDY trades at $12.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZYNE currently has a P/E ratio of -1.65, whereas RDY's P/E ratio is 20.30. In terms of profitability, ZYNE's ROE is -0.59%, compared to RDY's ROE of +0.09%. Regarding short-term risk, ZYNE is more volatile compared to RDY. This indicates higher risk in terms of short-term price fluctuations for ZYNE.Check RDY's competition here
Lantheus Holdings, Inc. (NASDAQ: LNTH)
ZYNE vs LNTH Comparison August 2026
Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZYNE stands at 70.1M. In comparison, LNTH has a market cap of 6.6B. Regarding current trading prices, ZYNE is priced at $1.30 on the NASDAQ, while LNTH trades at $100.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZYNE currently has a P/E ratio of -1.65, whereas LNTH's P/E ratio is 16.93. In terms of profitability, ZYNE's ROE is -0.59%, compared to LNTH's ROE of +0.23%. Regarding short-term risk, ZYNE is more volatile compared to LNTH. This indicates higher risk in terms of short-term price fluctuations for ZYNE.Check LNTH's competition here
Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX)
ZYNE vs AMRX Comparison August 2026
Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZYNE stands at 70.1M. In comparison, AMRX has a market cap of 5.6B. Regarding current trading prices, ZYNE is priced at $1.30 on the NASDAQ, while AMRX trades at $17.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZYNE currently has a P/E ratio of -1.65, whereas AMRX's P/E ratio is 19.62. In terms of profitability, ZYNE's ROE is -0.59%, compared to AMRX's ROE of -3.27%. Regarding short-term risk, ZYNE is more volatile compared to AMRX. This indicates higher risk in terms of short-term price fluctuations for ZYNE.Check AMRX's competition here
Indivior Pharmaceuticals Inc (NASDAQ: INDV)
ZYNE vs INDV Comparison August 2026
Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZYNE stands at 70.1M. In comparison, INDV has a market cap of 4.8B. Regarding current trading prices, ZYNE is priced at $1.30 on the NASDAQ, while INDV trades at $38.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZYNE currently has a P/E ratio of -1.65, whereas INDV's P/E ratio is 10.61. In terms of profitability, ZYNE's ROE is -0.59%, compared to INDV's ROE of -2.16%. Regarding short-term risk, ZYNE is more volatile compared to INDV. This indicates higher risk in terms of short-term price fluctuations for ZYNE.Check INDV's competition here
Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN)
ZYNE vs SUPN Comparison August 2026
Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZYNE stands at 70.1M. In comparison, SUPN has a market cap of 2.8B. Regarding current trading prices, ZYNE is priced at $1.30 on the NASDAQ, while SUPN trades at $47.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZYNE currently has a P/E ratio of -1.65, whereas SUPN's P/E ratio is 15.64. In terms of profitability, ZYNE's ROE is -0.59%, compared to SUPN's ROE of -0.10%. Regarding short-term risk, ZYNE is more volatile compared to SUPN. This indicates higher risk in terms of short-term price fluctuations for ZYNE.Check SUPN's competition here
Regencell Bioscience Holdings Limited (NASDAQ: RGC)
ZYNE vs RGC Comparison August 2026
Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZYNE stands at 70.1M. In comparison, RGC has a market cap of 2.5B. Regarding current trading prices, ZYNE is priced at $1.30 on the NASDAQ, while RGC trades at $5.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZYNE currently has a P/E ratio of -1.65, whereas RGC's P/E ratio is -356.34. In terms of profitability, ZYNE's ROE is -0.59%, compared to RGC's ROE of -2.32%. Regarding short-term risk, ZYNE is more volatile compared to RGC. This indicates higher risk in terms of short-term price fluctuations for ZYNE.Check RGC's competition here
Bausch Health Companies Inc. (NYSE: BHC)
ZYNE vs BHC Comparison August 2026
Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZYNE stands at 70.1M. In comparison, BHC has a market cap of 2.3B. Regarding current trading prices, ZYNE is priced at $1.30 on the NASDAQ, while BHC trades at $6.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZYNE currently has a P/E ratio of -1.65, whereas BHC's P/E ratio is 1.58. In terms of profitability, ZYNE's ROE is -0.59%, compared to BHC's ROE of +0.89%. Regarding short-term risk, ZYNE is more volatile compared to BHC. This indicates higher risk in terms of short-term price fluctuations for ZYNE.Check BHC's competition here
Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH)
ZYNE vs DCPH Comparison August 2026
Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZYNE stands at 70.1M. In comparison, DCPH has a market cap of 2.2B. Regarding current trading prices, ZYNE is priced at $1.30 on the NASDAQ, while DCPH trades at $25.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZYNE currently has a P/E ratio of -1.65, whereas DCPH's P/E ratio is -11.58. In terms of profitability, ZYNE's ROE is -0.59%, compared to DCPH's ROE of -0.56%. Regarding short-term risk, ZYNE is more volatile compared to DCPH. This indicates higher risk in terms of short-term price fluctuations for ZYNE.Check DCPH's competition here
HUTCHMED (China) Limited (NASDAQ: HCM)
ZYNE vs HCM Comparison August 2026
Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZYNE stands at 70.1M. In comparison, HCM has a market cap of 2.1B. Regarding current trading prices, ZYNE is priced at $1.30 on the NASDAQ, while HCM trades at $12.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZYNE currently has a P/E ratio of -1.65, whereas HCM's P/E ratio is 4.59. In terms of profitability, ZYNE's ROE is -0.59%, compared to HCM's ROE of +0.01%. Regarding short-term risk, ZYNE is more volatile compared to HCM. This indicates higher risk in terms of short-term price fluctuations for ZYNE.Check HCM's competition here
Avadel Pharmaceuticals plc (NASDAQ: AVDL)
ZYNE vs AVDL Comparison August 2026
Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZYNE stands at 70.1M. In comparison, AVDL has a market cap of 2.1B. Regarding current trading prices, ZYNE is priced at $1.30 on the NASDAQ, while AVDL trades at $21.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZYNE currently has a P/E ratio of -1.65, whereas AVDL's P/E ratio is -1082.00. In terms of profitability, ZYNE's ROE is -0.59%, compared to AVDL's ROE of +0.05%. Regarding short-term risk, ZYNE is more volatile compared to AVDL. This indicates higher risk in terms of short-term price fluctuations for ZYNE.Check AVDL's competition here
Embecta Corp. (NASDAQ: EMBCV)
ZYNE vs EMBCV Comparison August 2026
Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZYNE stands at 70.1M. In comparison, EMBCV has a market cap of 1.9B. Regarding current trading prices, ZYNE is priced at $1.30 on the NASDAQ, while EMBCV trades at $33.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZYNE currently has a P/E ratio of -1.65, whereas EMBCV's P/E ratio is N/A. In terms of profitability, ZYNE's ROE is -0.59%, compared to EMBCV's ROE of -0.19%. Regarding short-term risk, ZYNE is less volatile compared to EMBCV. This indicates lower risk in terms of short-term price fluctuations for ZYNE.Check EMBCV's competition here
Dynavax Technologies Corporation (NASDAQ: DVAX)
ZYNE vs DVAX Comparison August 2026
Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZYNE stands at 70.1M. In comparison, DVAX has a market cap of 1.8B. Regarding current trading prices, ZYNE is priced at $1.30 on the NASDAQ, while DVAX trades at $15.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZYNE currently has a P/E ratio of -1.65, whereas DVAX's P/E ratio is -41.89. In terms of profitability, ZYNE's ROE is -0.59%, compared to DVAX's ROE of -0.10%. Regarding short-term risk, ZYNE is more volatile compared to DVAX. This indicates higher risk in terms of short-term price fluctuations for ZYNE.Check DVAX's competition here
Perrigo Company plc (NYSE: PRGO)
ZYNE vs PRGO Comparison August 2026
Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZYNE stands at 70.1M. In comparison, PRGO has a market cap of 1.8B. Regarding current trading prices, ZYNE is priced at $1.30 on the NASDAQ, while PRGO trades at $12.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZYNE currently has a P/E ratio of -1.65, whereas PRGO's P/E ratio is 5.07. In terms of profitability, ZYNE's ROE is -0.59%, compared to PRGO's ROE of -0.56%. Regarding short-term risk, ZYNE is more volatile compared to PRGO. This indicates higher risk in terms of short-term price fluctuations for ZYNE.Check PRGO's competition here
ANI Pharmaceuticals, Inc. (NASDAQ: ANIP)
ZYNE vs ANIP Comparison August 2026
Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZYNE stands at 70.1M. In comparison, ANIP has a market cap of 1.7B. Regarding current trading prices, ZYNE is priced at $1.30 on the NASDAQ, while ANIP trades at $75.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZYNE currently has a P/E ratio of -1.65, whereas ANIP's P/E ratio is 9.14. In terms of profitability, ZYNE's ROE is -0.59%, compared to ANIP's ROE of +0.19%. Regarding short-term risk, ZYNE is more volatile compared to ANIP. This indicates higher risk in terms of short-term price fluctuations for ZYNE.Check ANIP's competition here
Taro Pharmaceutical Industries Ltd. (NYSE: TARO)
ZYNE vs TARO Comparison August 2026
Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZYNE stands at 70.1M. In comparison, TARO has a market cap of 1.6B. Regarding current trading prices, ZYNE is priced at $1.30 on the NASDAQ, while TARO trades at $42.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZYNE currently has a P/E ratio of -1.65, whereas TARO's P/E ratio is 30.05. In terms of profitability, ZYNE's ROE is -0.59%, compared to TARO's ROE of +0.03%. Regarding short-term risk, ZYNE is more volatile compared to TARO. This indicates higher risk in terms of short-term price fluctuations for ZYNE.Check TARO's competition here
Harrow Health, Inc. (NASDAQ: HROW)
ZYNE vs HROW Comparison August 2026
Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZYNE stands at 70.1M. In comparison, HROW has a market cap of 1.5B. Regarding current trading prices, ZYNE is priced at $1.30 on the NASDAQ, while HROW trades at $39.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZYNE currently has a P/E ratio of -1.65, whereas HROW's P/E ratio is 437.33. In terms of profitability, ZYNE's ROE is -0.59%, compared to HROW's ROE of -1.04%. Regarding short-term risk, ZYNE is more volatile compared to HROW. This indicates higher risk in terms of short-term price fluctuations for ZYNE.Check HROW's competition here
Phibro Animal Health Corporation (NASDAQ: PAHC)
ZYNE vs PAHC Comparison August 2026
Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZYNE stands at 70.1M. In comparison, PAHC has a market cap of 1.4B. Regarding current trading prices, ZYNE is priced at $1.30 on the NASDAQ, while PAHC trades at $34.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZYNE currently has a P/E ratio of -1.65, whereas PAHC's P/E ratio is 11.54. In terms of profitability, ZYNE's ROE is -0.59%, compared to PAHC's ROE of +0.29%. Regarding short-term risk, ZYNE is more volatile compared to PAHC. This indicates higher risk in terms of short-term price fluctuations for ZYNE.Check PAHC's competition here
Alvotech (NASDAQ: ALVO)
ZYNE vs ALVO Comparison August 2026
Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZYNE stands at 70.1M. In comparison, ALVO has a market cap of 1.4B. Regarding current trading prices, ZYNE is priced at $1.30 on the NASDAQ, while ALVO trades at $3.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZYNE currently has a P/E ratio of -1.65, whereas ALVO's P/E ratio is -11.79. In terms of profitability, ZYNE's ROE is -0.59%, compared to ALVO's ROE of +0.35%. Regarding short-term risk, ZYNE is more volatile compared to ALVO. This indicates higher risk in terms of short-term price fluctuations for ZYNE.Check ALVO's competition here
Cronos Group Inc. (NASDAQ: CRON)
ZYNE vs CRON Comparison August 2026
Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZYNE stands at 70.1M. In comparison, CRON has a market cap of 1.2B. Regarding current trading prices, ZYNE is priced at $1.30 on the NASDAQ, while CRON trades at $3.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZYNE currently has a P/E ratio of -1.65, whereas CRON's P/E ratio is 30.10. In terms of profitability, ZYNE's ROE is -0.59%, compared to CRON's ROE of +0.06%. Regarding short-term risk, ZYNE is more volatile compared to CRON. This indicates higher risk in terms of short-term price fluctuations for ZYNE.Check CRON's competition here
Eton Pharmaceuticals, Inc. (NASDAQ: ETON)
ZYNE vs ETON Comparison August 2026
Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZYNE stands at 70.1M. In comparison, ETON has a market cap of 1.1B. Regarding current trading prices, ZYNE is priced at $1.30 on the NASDAQ, while ETON trades at $42.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZYNE currently has a P/E ratio of -1.65, whereas ETON's P/E ratio is -594.00. In terms of profitability, ZYNE's ROE is -0.59%, compared to ETON's ROE of -0.06%. Regarding short-term risk, ZYNE is more volatile compared to ETON. This indicates higher risk in terms of short-term price fluctuations for ZYNE.Check ETON's competition here
Pacira BioSciences, Inc. (NASDAQ: PCRX)
ZYNE vs PCRX Comparison August 2026
Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZYNE stands at 70.1M. In comparison, PCRX has a market cap of 932.2M. Regarding current trading prices, ZYNE is priced at $1.30 on the NASDAQ, while PCRX trades at $23.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZYNE currently has a P/E ratio of -1.65, whereas PCRX's P/E ratio is 9.12. In terms of profitability, ZYNE's ROE is -0.59%, compared to PCRX's ROE of +0.02%. Regarding short-term risk, ZYNE is more volatile compared to PCRX. This indicates higher risk in terms of short-term price fluctuations for ZYNE.Check PCRX's competition here
PetIQ, Inc. (NASDAQ: PETQ)
ZYNE vs PETQ Comparison August 2026
Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZYNE stands at 70.1M. In comparison, PETQ has a market cap of 919.2M. Regarding current trading prices, ZYNE is priced at $1.30 on the NASDAQ, while PETQ trades at $30.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZYNE currently has a P/E ratio of -1.65, whereas PETQ's P/E ratio is 83.73. In terms of profitability, ZYNE's ROE is -0.59%, compared to PETQ's ROE of +0.01%. Regarding short-term risk, ZYNE is more volatile compared to PETQ. This indicates higher risk in terms of short-term price fluctuations for ZYNE.Check PETQ's competition here
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH)
ZYNE vs AMPH Comparison August 2026
Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZYNE stands at 70.1M. In comparison, AMPH has a market cap of 881M. Regarding current trading prices, ZYNE is priced at $1.30 on the NASDAQ, while AMPH trades at $20.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZYNE currently has a P/E ratio of -1.65, whereas AMPH's P/E ratio is 6.82. In terms of profitability, ZYNE's ROE is -0.59%, compared to AMPH's ROE of +0.10%. Regarding short-term risk, ZYNE is more volatile compared to AMPH. This indicates higher risk in terms of short-term price fluctuations for ZYNE.Check AMPH's competition here
Collegium Pharmaceutical, Inc. (NASDAQ: COLL)
ZYNE vs COLL Comparison August 2026
Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZYNE stands at 70.1M. In comparison, COLL has a market cap of 842.6M. Regarding current trading prices, ZYNE is priced at $1.30 on the NASDAQ, while COLL trades at $28.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZYNE currently has a P/E ratio of -1.65, whereas COLL's P/E ratio is 3.26. In terms of profitability, ZYNE's ROE is -0.59%, compared to COLL's ROE of +0.16%. Regarding short-term risk, ZYNE is more volatile compared to COLL. This indicates higher risk in terms of short-term price fluctuations for ZYNE.Check COLL's competition here
Evotec SE (NASDAQ: EVO)
ZYNE vs EVO Comparison August 2026
Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZYNE stands at 70.1M. In comparison, EVO has a market cap of 778M. Regarding current trading prices, ZYNE is priced at $1.30 on the NASDAQ, while EVO trades at $2.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZYNE currently has a P/E ratio of -1.65, whereas EVO's P/E ratio is -3.09. In terms of profitability, ZYNE's ROE is -0.59%, compared to EVO's ROE of -0.24%. Regarding short-term risk, ZYNE is more volatile compared to EVO. This indicates higher risk in terms of short-term price fluctuations for ZYNE.Check EVO's competition here
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD)
ZYNE vs IRWD Comparison August 2026
Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZYNE stands at 70.1M. In comparison, IRWD has a market cap of 711.1M. Regarding current trading prices, ZYNE is priced at $1.30 on the NASDAQ, while IRWD trades at $4.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZYNE currently has a P/E ratio of -1.65, whereas IRWD's P/E ratio is 5.54. In terms of profitability, ZYNE's ROE is -0.59%, compared to IRWD's ROE of -0.57%. Regarding short-term risk, ZYNE is more volatile compared to IRWD. This indicates higher risk in terms of short-term price fluctuations for ZYNE.Check IRWD's competition here
BioDelivery Sciences International, Inc. (NASDAQ: BDSI)
ZYNE vs BDSI Comparison August 2026
Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZYNE stands at 70.1M. In comparison, BDSI has a market cap of 577.1M. Regarding current trading prices, ZYNE is priced at $1.30 on the NASDAQ, while BDSI trades at $5.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZYNE currently has a P/E ratio of -1.65, whereas BDSI's P/E ratio is 6.82. In terms of profitability, ZYNE's ROE is -0.59%, compared to BDSI's ROE of +0.57%. Regarding short-term risk, ZYNE is more volatile compared to BDSI. This indicates higher risk in terms of short-term price fluctuations for ZYNE.Check BDSI's competition here
Evolus, Inc. (NASDAQ: EOLS)
ZYNE vs EOLS Comparison August 2026
Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZYNE stands at 70.1M. In comparison, EOLS has a market cap of 534.7M. Regarding current trading prices, ZYNE is priced at $1.30 on the NASDAQ, while EOLS trades at $8.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZYNE currently has a P/E ratio of -1.65, whereas EOLS's P/E ratio is -25.71. In terms of profitability, ZYNE's ROE is -0.59%, compared to EOLS's ROE of +1.23%. Regarding short-term risk, ZYNE is more volatile compared to EOLS. This indicates higher risk in terms of short-term price fluctuations for ZYNE.Check EOLS's competition here
Aquestive Therapeutics, Inc. (NASDAQ: AQST)
ZYNE vs AQST Comparison August 2026
Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZYNE stands at 70.1M. In comparison, AQST has a market cap of 530.7M. Regarding current trading prices, ZYNE is priced at $1.30 on the NASDAQ, while AQST trades at $4.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZYNE currently has a P/E ratio of -1.65, whereas AQST's P/E ratio is -6.93. In terms of profitability, ZYNE's ROE is -0.59%, compared to AQST's ROE of +2.44%. Regarding short-term risk, ZYNE is more volatile compared to AQST. This indicates higher risk in terms of short-term price fluctuations for ZYNE.Check AQST's competition here
Tilray Brands, Inc. (NASDAQ: TLRY)
ZYNE vs TLRY Comparison August 2026
Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZYNE stands at 70.1M. In comparison, TLRY has a market cap of 523.4M. Regarding current trading prices, ZYNE is priced at $1.30 on the NASDAQ, while TLRY trades at $4.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZYNE currently has a P/E ratio of -1.65, whereas TLRY's P/E ratio is -4.32. In terms of profitability, ZYNE's ROE is -0.59%, compared to TLRY's ROE of -0.08%. Regarding short-term risk, ZYNE is more volatile compared to TLRY. This indicates higher risk in terms of short-term price fluctuations for ZYNE.Check TLRY's competition here
Canopy Growth Corporation (NASDAQ: CGC)
ZYNE vs CGC Comparison August 2026
Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZYNE stands at 70.1M. In comparison, CGC has a market cap of 432.7M. Regarding current trading prices, ZYNE is priced at $1.30 on the NASDAQ, while CGC trades at $1.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZYNE currently has a P/E ratio of -1.65, whereas CGC's P/E ratio is -0.62. In terms of profitability, ZYNE's ROE is -0.59%, compared to CGC's ROE of -0.33%. Regarding short-term risk, ZYNE is more volatile compared to CGC. This indicates higher risk in terms of short-term price fluctuations for ZYNE.Check CGC's competition here
Kamada Ltd. (NASDAQ: KMDA)
ZYNE vs KMDA Comparison August 2026
Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZYNE stands at 70.1M. In comparison, KMDA has a market cap of 396.9M. Regarding current trading prices, ZYNE is priced at $1.30 on the NASDAQ, while KMDA trades at $7.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZYNE currently has a P/E ratio of -1.65, whereas KMDA's P/E ratio is 19.66. In terms of profitability, ZYNE's ROE is -0.59%, compared to KMDA's ROE of +0.08%. Regarding short-term risk, ZYNE is more volatile compared to KMDA. This indicates higher risk in terms of short-term price fluctuations for ZYNE.Check KMDA's competition here
Alpha Teknova, Inc. (NASDAQ: TKNO)
ZYNE vs TKNO Comparison August 2026
Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZYNE stands at 70.1M. In comparison, TKNO has a market cap of 396.2M. Regarding current trading prices, ZYNE is priced at $1.30 on the NASDAQ, while TKNO trades at $7.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZYNE currently has a P/E ratio of -1.65, whereas TKNO's P/E ratio is -23.84. In terms of profitability, ZYNE's ROE is -0.59%, compared to TKNO's ROE of -0.25%. Regarding short-term risk, ZYNE is more volatile compared to TKNO. This indicates higher risk in terms of short-term price fluctuations for ZYNE.Check TKNO's competition here
Alimera Sciences, Inc. (NASDAQ: ALIM)
ZYNE vs ALIM Comparison August 2026
Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZYNE stands at 70.1M. In comparison, ALIM has a market cap of 301.3M. Regarding current trading prices, ZYNE is priced at $1.30 on the NASDAQ, while ALIM trades at $5.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZYNE currently has a P/E ratio of -1.65, whereas ALIM's P/E ratio is 5.28. In terms of profitability, ZYNE's ROE is -0.59%, compared to ALIM's ROE of -1.59%. Regarding short-term risk, ZYNE is more volatile compared to ALIM. This indicates higher risk in terms of short-term price fluctuations for ZYNE.Check ALIM's competition here
Embecta Corp. (NASDAQ: EMBC)
ZYNE vs EMBC Comparison August 2026
Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZYNE stands at 70.1M. In comparison, EMBC has a market cap of 281.8M. Regarding current trading prices, ZYNE is priced at $1.30 on the NASDAQ, while EMBC trades at $5.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZYNE currently has a P/E ratio of -1.65, whereas EMBC's P/E ratio is 1.83. In terms of profitability, ZYNE's ROE is -0.59%, compared to EMBC's ROE of -0.14%. Regarding short-term risk, ZYNE is less volatile compared to EMBC. This indicates lower risk in terms of short-term price fluctuations for ZYNE.Check EMBC's competition here
Landec Corporation (NASDAQ: LNDC)
ZYNE vs LNDC Comparison August 2026
Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZYNE stands at 70.1M. In comparison, LNDC has a market cap of 263.6M. Regarding current trading prices, ZYNE is priced at $1.30 on the NASDAQ, while LNDC trades at $8.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZYNE currently has a P/E ratio of -1.65, whereas LNDC's P/E ratio is -4.04. In terms of profitability, ZYNE's ROE is -0.59%, compared to LNDC's ROE of +6.44%. Regarding short-term risk, ZYNE is more volatile compared to LNDC. This indicates higher risk in terms of short-term price fluctuations for ZYNE.Check LNDC's competition here
Aurora Cannabis Inc. (NASDAQ: ACB)
ZYNE vs ACB Comparison August 2026
Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZYNE stands at 70.1M. In comparison, ACB has a market cap of 236.6M. Regarding current trading prices, ZYNE is priced at $1.30 on the NASDAQ, while ACB trades at $3.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZYNE currently has a P/E ratio of -1.65, whereas ACB's P/E ratio is -7.80. In terms of profitability, ZYNE's ROE is -0.59%, compared to ACB's ROE of -0.21%. Regarding short-term risk, ZYNE is more volatile compared to ACB. This indicates higher risk in terms of short-term price fluctuations for ZYNE.Check ACB's competition here
Organogenesis Holdings Inc. (NASDAQ: ORGO)
ZYNE vs ORGO Comparison August 2026
Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZYNE stands at 70.1M. In comparison, ORGO has a market cap of 232.9M. Regarding current trading prices, ZYNE is priced at $1.30 on the NASDAQ, while ORGO trades at $1.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZYNE currently has a P/E ratio of -1.65, whereas ORGO's P/E ratio is 60.33. In terms of profitability, ZYNE's ROE is -0.59%, compared to ORGO's ROE of -0.24%. Regarding short-term risk, ZYNE is more volatile compared to ORGO. This indicates higher risk in terms of short-term price fluctuations for ZYNE.Check ORGO's competition here
Shineco, Inc. (NASDAQ: TYHT)
ZYNE vs TYHT Comparison August 2026
Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZYNE stands at 70.1M. In comparison, TYHT has a market cap of 229.2M. Regarding current trading prices, ZYNE is priced at $1.30 on the NASDAQ, while TYHT trades at $11.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZYNE currently has a P/E ratio of -1.65, whereas TYHT's P/E ratio is -1.61. In terms of profitability, ZYNE's ROE is -0.59%, compared to TYHT's ROE of -0.57%. Regarding short-term risk, ZYNE is more volatile compared to TYHT. This indicates higher risk in terms of short-term price fluctuations for ZYNE.Check TYHT's competition here
SIGA Technologies, Inc. (NASDAQ: SIGA)
ZYNE vs SIGA Comparison August 2026
Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZYNE stands at 70.1M. In comparison, SIGA has a market cap of 205.8M. Regarding current trading prices, ZYNE is priced at $1.30 on the NASDAQ, while SIGA trades at $2.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZYNE currently has a P/E ratio of -1.65, whereas SIGA's P/E ratio is 10.63. In terms of profitability, ZYNE's ROE is -0.59%, compared to SIGA's ROE of -0.02%. Regarding short-term risk, ZYNE is more volatile compared to SIGA. This indicates higher risk in terms of short-term price fluctuations for ZYNE.Check SIGA's competition here
Organigram Global Inc. (NASDAQ: OGI)
ZYNE vs OGI Comparison August 2026
Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZYNE stands at 70.1M. In comparison, OGI has a market cap of 181.6M. Regarding current trading prices, ZYNE is priced at $1.30 on the NASDAQ, while OGI trades at $1.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZYNE currently has a P/E ratio of -1.65, whereas OGI's P/E ratio is -4.96. In terms of profitability, ZYNE's ROE is -0.59%, compared to OGI's ROE of -0.07%. Regarding short-term risk, ZYNE is more volatile compared to OGI. This indicates higher risk in terms of short-term price fluctuations for ZYNE.Check OGI's competition here
Lifecore Biomedical, Inc. (NASDAQ: LFCR)
ZYNE vs LFCR Comparison August 2026
Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZYNE stands at 70.1M. In comparison, LFCR has a market cap of 178.9M. Regarding current trading prices, ZYNE is priced at $1.30 on the NASDAQ, while LFCR trades at $4.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZYNE currently has a P/E ratio of -1.65, whereas LFCR's P/E ratio is -4.46. In terms of profitability, ZYNE's ROE is -0.59%, compared to LFCR's ROE of -2.51%. Regarding short-term risk, ZYNE is more volatile compared to LFCR. This indicates higher risk in terms of short-term price fluctuations for ZYNE.Check LFCR's competition here
Recro Pharma, Inc. (NASDAQ: REPH)
ZYNE vs REPH Comparison August 2026
Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZYNE stands at 70.1M. In comparison, REPH has a market cap of 177.4M. Regarding current trading prices, ZYNE is priced at $1.30 on the NASDAQ, while REPH trades at $2.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZYNE currently has a P/E ratio of -1.65, whereas REPH's P/E ratio is -8.04. In terms of profitability, ZYNE's ROE is -0.59%, compared to REPH's ROE of -0.22%. Regarding short-term risk, ZYNE is less volatile compared to REPH. This indicates lower risk in terms of short-term price fluctuations for ZYNE.Check REPH's competition here
Journey Medical Corporation (NASDAQ: DERM)
ZYNE vs DERM Comparison August 2026
Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZYNE stands at 70.1M. In comparison, DERM has a market cap of 177M. Regarding current trading prices, ZYNE is priced at $1.30 on the NASDAQ, while DERM trades at $6.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZYNE currently has a P/E ratio of -1.65, whereas DERM's P/E ratio is -17.38. In terms of profitability, ZYNE's ROE is -0.59%, compared to DERM's ROE of -0.36%. Regarding short-term risk, ZYNE is less volatile compared to DERM. This indicates lower risk in terms of short-term price fluctuations for ZYNE.Check DERM's competition here
Cardiol Therapeutics Inc. (NASDAQ: CRDL)
ZYNE vs CRDL Comparison August 2026
Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZYNE stands at 70.1M. In comparison, CRDL has a market cap of 175.2M. Regarding current trading prices, ZYNE is priced at $1.30 on the NASDAQ, while CRDL trades at $1.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZYNE currently has a P/E ratio of -1.65, whereas CRDL's P/E ratio is -5.41. In terms of profitability, ZYNE's ROE is -0.59%, compared to CRDL's ROE of -2.29%. Regarding short-term risk, ZYNE is less volatile compared to CRDL. This indicates lower risk in terms of short-term price fluctuations for ZYNE.Check CRDL's competition here
Theratechnologies Inc. (NASDAQ: THTX)
ZYNE vs THTX Comparison August 2026
Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZYNE stands at 70.1M. In comparison, THTX has a market cap of 155.9M. Regarding current trading prices, ZYNE is priced at $1.30 on the NASDAQ, while THTX trades at $3.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZYNE currently has a P/E ratio of -1.65, whereas THTX's P/E ratio is -28.83. In terms of profitability, ZYNE's ROE is -0.59%, compared to THTX's ROE of +0.17%. Regarding short-term risk, ZYNE is more volatile compared to THTX. This indicates higher risk in terms of short-term price fluctuations for ZYNE.Check THTX's competition here
Assertio Holdings, Inc. (NASDAQ: ASRT)
ZYNE vs ASRT Comparison August 2026
Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZYNE stands at 70.1M. In comparison, ASRT has a market cap of 151.9M. Regarding current trading prices, ZYNE is priced at $1.30 on the NASDAQ, while ASRT trades at $23.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZYNE currently has a P/E ratio of -1.65, whereas ASRT's P/E ratio is -7.10. In terms of profitability, ZYNE's ROE is -0.59%, compared to ASRT's ROE of -0.39%. Regarding short-term risk, ZYNE is more volatile compared to ASRT. This indicates higher risk in terms of short-term price fluctuations for ZYNE.Check ASRT's competition here
Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX)
ZYNE vs CPIX Comparison August 2026
Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZYNE stands at 70.1M. In comparison, CPIX has a market cap of 119.3M. Regarding current trading prices, ZYNE is priced at $1.30 on the NASDAQ, while CPIX trades at $7.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZYNE currently has a P/E ratio of -1.65, whereas CPIX's P/E ratio is -19.90. In terms of profitability, ZYNE's ROE is -0.59%, compared to CPIX's ROE of -0.47%. Regarding short-term risk, ZYNE is more volatile compared to CPIX. This indicates higher risk in terms of short-term price fluctuations for ZYNE.Check CPIX's competition here
Societal CDMO, Inc. (NASDAQ: SCTL)
ZYNE vs SCTL Comparison August 2026
Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZYNE stands at 70.1M. In comparison, SCTL has a market cap of 116.1M. Regarding current trading prices, ZYNE is priced at $1.30 on the NASDAQ, while SCTL trades at $1.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZYNE currently has a P/E ratio of -1.65, whereas SCTL's P/E ratio is -7.86. In terms of profitability, ZYNE's ROE is -0.59%, compared to SCTL's ROE of -0.22%. Regarding short-term risk, ZYNE is more volatile compared to SCTL. This indicates higher risk in terms of short-term price fluctuations for ZYNE.Check SCTL's competition here
BGM Group Ltd. (NASDAQ: BGM)
ZYNE vs BGM Comparison August 2026
Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZYNE stands at 70.1M. In comparison, BGM has a market cap of 111.9M. Regarding current trading prices, ZYNE is priced at $1.30 on the NASDAQ, while BGM trades at $0.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZYNE currently has a P/E ratio of -1.65, whereas BGM's P/E ratio is -1.01. In terms of profitability, ZYNE's ROE is -0.59%, compared to BGM's ROE of -0.07%. Regarding short-term risk, ZYNE is more volatile compared to BGM. This indicates higher risk in terms of short-term price fluctuations for ZYNE.Check BGM's competition here
Procaps Group S.A. (NASDAQ: PROC)
ZYNE vs PROC Comparison August 2026
Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZYNE stands at 70.1M. In comparison, PROC has a market cap of 102.1M. Regarding current trading prices, ZYNE is priced at $1.30 on the NASDAQ, while PROC trades at $1.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZYNE currently has a P/E ratio of -1.65, whereas PROC's P/E ratio is 1.53. In terms of profitability, ZYNE's ROE is -0.59%, compared to PROC's ROE of -2.22%. Regarding short-term risk, ZYNE is more volatile compared to PROC. This indicates higher risk in terms of short-term price fluctuations for ZYNE.Check PROC's competition here
OptiNose, Inc. (NASDAQ: OPTN)
ZYNE vs OPTN Comparison August 2026
Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZYNE stands at 70.1M. In comparison, OPTN has a market cap of 97.2M. Regarding current trading prices, ZYNE is priced at $1.30 on the NASDAQ, while OPTN trades at $9.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZYNE currently has a P/E ratio of -1.65, whereas OPTN's P/E ratio is -4.42. In terms of profitability, ZYNE's ROE is -0.59%, compared to OPTN's ROE of +0.34%. Regarding short-term risk, ZYNE is more volatile compared to OPTN. This indicates higher risk in terms of short-term price fluctuations for ZYNE.Check OPTN's competition here
Zomedica Corp. (AMEX: ZOM)
ZYNE vs ZOM Comparison August 2026
Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZYNE stands at 70.1M. In comparison, ZOM has a market cap of 95.3M. Regarding current trading prices, ZYNE is priced at $1.30 on the NASDAQ, while ZOM trades at $0.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZYNE currently has a P/E ratio of -1.65, whereas ZOM's P/E ratio is -1.62. In terms of profitability, ZYNE's ROE is -0.59%, compared to ZOM's ROE of -0.17%. Regarding short-term risk, ZYNE is more volatile compared to ZOM. This indicates higher risk in terms of short-term price fluctuations for ZYNE.Check ZOM's competition here
Upexi, Inc. (NASDAQ: GRVI)
ZYNE vs GRVI Comparison August 2026
Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZYNE stands at 70.1M. In comparison, GRVI has a market cap of 88.9M. Regarding current trading prices, ZYNE is priced at $1.30 on the NASDAQ, while GRVI trades at $4.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZYNE currently has a P/E ratio of -1.65, whereas GRVI's P/E ratio is 26.05. In terms of profitability, ZYNE's ROE is -0.59%, compared to GRVI's ROE of -2.54%. Regarding short-term risk, ZYNE is less volatile compared to GRVI. This indicates lower risk in terms of short-term price fluctuations for ZYNE.Check GRVI's competition here
Zhengye Biotechnology Holding Limited (NASDAQ: ZYBT)
ZYNE vs ZYBT Comparison August 2026
Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZYNE stands at 70.1M. In comparison, ZYBT has a market cap of 73.5M. Regarding current trading prices, ZYNE is priced at $1.30 on the NASDAQ, while ZYBT trades at $1.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZYNE currently has a P/E ratio of -1.65, whereas ZYBT's P/E ratio is -7.05. In terms of profitability, ZYNE's ROE is -0.59%, compared to ZYBT's ROE of -0.27%. Regarding short-term risk, ZYNE is less volatile compared to ZYBT. This indicates lower risk in terms of short-term price fluctuations for ZYNE.Check ZYBT's competition here
Talphera, Inc. (NASDAQ: TLPH)
ZYNE vs TLPH Comparison August 2026
Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZYNE stands at 70.1M. In comparison, TLPH has a market cap of 72.7M. Regarding current trading prices, ZYNE is priced at $1.30 on the NASDAQ, while TLPH trades at $1.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZYNE currently has a P/E ratio of -1.65, whereas TLPH's P/E ratio is -4.52. In terms of profitability, ZYNE's ROE is -0.59%, compared to TLPH's ROE of -0.93%. Regarding short-term risk, ZYNE is less volatile compared to TLPH. This indicates lower risk in terms of short-term price fluctuations for ZYNE.Check TLPH's competition here
Silver Spike Investment Corp. (NASDAQ: SSIC)
ZYNE vs SSIC Comparison August 2026
Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZYNE stands at 70.1M. In comparison, SSIC has a market cap of 66.7M. Regarding current trading prices, ZYNE is priced at $1.30 on the NASDAQ, while SSIC trades at $10.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZYNE currently has a P/E ratio of -1.65, whereas SSIC's P/E ratio is 11.93. In terms of profitability, ZYNE's ROE is -0.59%, compared to SSIC's ROE of +0.00%. Regarding short-term risk, ZYNE is more volatile compared to SSIC. This indicates higher risk in terms of short-term price fluctuations for ZYNE.Check SSIC's competition here
The Valens Company Inc. (NASDAQ: VLNS)
ZYNE vs VLNS Comparison August 2026
Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZYNE stands at 70.1M. In comparison, VLNS has a market cap of 61.5M. Regarding current trading prices, ZYNE is priced at $1.30 on the NASDAQ, while VLNS trades at $0.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZYNE currently has a P/E ratio of -1.65, whereas VLNS's P/E ratio is -1.03. In terms of profitability, ZYNE's ROE is -0.59%, compared to VLNS's ROE of N/A. Regarding short-term risk, ZYNE is more volatile compared to VLNS. This indicates higher risk in terms of short-term price fluctuations for ZYNE.Check VLNS's competition here
DURECT Corporation (NASDAQ: DRRX)
ZYNE vs DRRX Comparison August 2026
Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZYNE stands at 70.1M. In comparison, DRRX has a market cap of 59.3M. Regarding current trading prices, ZYNE is priced at $1.30 on the NASDAQ, while DRRX trades at $1.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZYNE currently has a P/E ratio of -1.65, whereas DRRX's P/E ratio is -4.44. In terms of profitability, ZYNE's ROE is -0.59%, compared to DRRX's ROE of -1.40%. Regarding short-term risk, ZYNE is more volatile compared to DRRX. This indicates higher risk in terms of short-term price fluctuations for ZYNE.Check DRRX's competition here
InterCure Ltd. (NASDAQ: INCR)
ZYNE vs INCR Comparison August 2026
Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZYNE stands at 70.1M. In comparison, INCR has a market cap of 57.1M. Regarding current trading prices, ZYNE is priced at $1.30 on the NASDAQ, while INCR trades at $0.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZYNE currently has a P/E ratio of -1.65, whereas INCR's P/E ratio is -2.23. In terms of profitability, ZYNE's ROE is -0.59%, compared to INCR's ROE of -0.09%. Regarding short-term risk, ZYNE is more volatile compared to INCR. This indicates higher risk in terms of short-term price fluctuations for ZYNE.Check INCR's competition here
Jupiter Wellness, Inc. (NASDAQ: JUPW)
ZYNE vs JUPW Comparison August 2026
Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZYNE stands at 70.1M. In comparison, JUPW has a market cap of 49.3M. Regarding current trading prices, ZYNE is priced at $1.30 on the NASDAQ, while JUPW trades at $1.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZYNE currently has a P/E ratio of -1.65, whereas JUPW's P/E ratio is -2.41. In terms of profitability, ZYNE's ROE is -0.59%, compared to JUPW's ROE of -1.94%. Regarding short-term risk, ZYNE is less volatile compared to JUPW. This indicates lower risk in terms of short-term price fluctuations for ZYNE.Check JUPW's competition here
China Pharma Holdings, Inc. (AMEX: CPHI)
ZYNE vs CPHI Comparison August 2026
Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZYNE stands at 70.1M. In comparison, CPHI has a market cap of 44.6M. Regarding current trading prices, ZYNE is priced at $1.30 on the NASDAQ, while CPHI trades at $1.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZYNE currently has a P/E ratio of -1.65, whereas CPHI's P/E ratio is -1.72. In terms of profitability, ZYNE's ROE is -0.59%, compared to CPHI's ROE of -0.19%. Regarding short-term risk, ZYNE is less volatile compared to CPHI. This indicates lower risk in terms of short-term price fluctuations for ZYNE.Check CPHI's competition here
Qilian International Holding Group Limited (NASDAQ: QLI)
ZYNE vs QLI Comparison August 2026
Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZYNE stands at 70.1M. In comparison, QLI has a market cap of 38.7M. Regarding current trading prices, ZYNE is priced at $1.30 on the NASDAQ, while QLI trades at $5.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZYNE currently has a P/E ratio of -1.65, whereas QLI's P/E ratio is -4.92. In terms of profitability, ZYNE's ROE is -0.59%, compared to QLI's ROE of -0.16%. Regarding short-term risk, ZYNE is more volatile compared to QLI. This indicates higher risk in terms of short-term price fluctuations for ZYNE.Check QLI's competition here
HEXO Corp. (NASDAQ: HEXO)
ZYNE vs HEXO Comparison August 2026
Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZYNE stands at 70.1M. In comparison, HEXO has a market cap of 31.2M. Regarding current trading prices, ZYNE is priced at $1.30 on the NASDAQ, while HEXO trades at $0.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZYNE currently has a P/E ratio of -1.65, whereas HEXO's P/E ratio is -0.26. In terms of profitability, ZYNE's ROE is -0.59%, compared to HEXO's ROE of -2.06%. Regarding short-term risk, ZYNE is less volatile compared to HEXO. This indicates lower risk in terms of short-term price fluctuations for ZYNE.Check HEXO's competition here
Rockwell Medical, Inc. (NASDAQ: RMTI)
ZYNE vs RMTI Comparison August 2026
Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZYNE stands at 70.1M. In comparison, RMTI has a market cap of 30.8M. Regarding current trading prices, ZYNE is priced at $1.30 on the NASDAQ, while RMTI trades at $7.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZYNE currently has a P/E ratio of -1.65, whereas RMTI's P/E ratio is -7.42. In terms of profitability, ZYNE's ROE is -0.59%, compared to RMTI's ROE of -0.15%. Regarding short-term risk, ZYNE is less volatile compared to RMTI. This indicates lower risk in terms of short-term price fluctuations for ZYNE.Check RMTI's competition here
Aytu BioPharma, Inc. (NASDAQ: AYTU)
ZYNE vs AYTU Comparison August 2026
Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZYNE stands at 70.1M. In comparison, AYTU has a market cap of 25.3M. Regarding current trading prices, ZYNE is priced at $1.30 on the NASDAQ, while AYTU trades at $2.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZYNE currently has a P/E ratio of -1.65, whereas AYTU's P/E ratio is -1.23. In terms of profitability, ZYNE's ROE is -0.59%, compared to AYTU's ROE of -1.49%. Regarding short-term risk, ZYNE is more volatile compared to AYTU. This indicates higher risk in terms of short-term price fluctuations for ZYNE.Check AYTU's competition here
TherapeuticsMD, Inc. (NASDAQ: TXMD)
ZYNE vs TXMD Comparison August 2026
Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZYNE stands at 70.1M. In comparison, TXMD has a market cap of 24.1M. Regarding current trading prices, ZYNE is priced at $1.30 on the NASDAQ, while TXMD trades at $2.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZYNE currently has a P/E ratio of -1.65, whereas TXMD's P/E ratio is 105.96. In terms of profitability, ZYNE's ROE is -0.59%, compared to TXMD's ROE of -0.01%. Regarding short-term risk, ZYNE is more volatile compared to TXMD. This indicates higher risk in terms of short-term price fluctuations for ZYNE.Check TXMD's competition here
Cyclo Therapeutics, Inc. (NASDAQ: CYTH)
ZYNE vs CYTH Comparison August 2026
Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZYNE stands at 70.1M. In comparison, CYTH has a market cap of 23.6M. Regarding current trading prices, ZYNE is priced at $1.30 on the NASDAQ, while CYTH trades at $0.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZYNE currently has a P/E ratio of -1.65, whereas CYTH's P/E ratio is -0.80. In terms of profitability, ZYNE's ROE is -0.59%, compared to CYTH's ROE of -7.30%. Regarding short-term risk, ZYNE is more volatile compared to CYTH. This indicates higher risk in terms of short-term price fluctuations for ZYNE.Check CYTH's competition here
Evoke Pharma, Inc. (NASDAQ: EVOK)
ZYNE vs EVOK Comparison August 2026
Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZYNE stands at 70.1M. In comparison, EVOK has a market cap of 18.9M. Regarding current trading prices, ZYNE is priced at $1.30 on the NASDAQ, while EVOK trades at $11.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZYNE currently has a P/E ratio of -1.65, whereas EVOK's P/E ratio is -7.97. In terms of profitability, ZYNE's ROE is -0.59%, compared to EVOK's ROE of -0.89%. Regarding short-term risk, ZYNE is more volatile compared to EVOK. This indicates higher risk in terms of short-term price fluctuations for ZYNE.Check EVOK's competition here
Optimi Health Corp. (NASDAQ: OPTH)
ZYNE vs OPTH Comparison August 2026
Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZYNE stands at 70.1M. In comparison, OPTH has a market cap of 15.3M. Regarding current trading prices, ZYNE is priced at $1.30 on the NASDAQ, while OPTH trades at $4.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZYNE currently has a P/E ratio of -1.65, whereas OPTH's P/E ratio is -17.38. In terms of profitability, ZYNE's ROE is -0.59%, compared to OPTH's ROE of -0.94%. Regarding short-term risk, ZYNE is more volatile compared to OPTH. This indicates higher risk in terms of short-term price fluctuations for ZYNE.Check OPTH's competition here
AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX)
ZYNE vs ACRX Comparison August 2026
Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZYNE stands at 70.1M. In comparison, ACRX has a market cap of 14.6M. Regarding current trading prices, ZYNE is priced at $1.30 on the NASDAQ, while ACRX trades at $0.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZYNE currently has a P/E ratio of -1.65, whereas ACRX's P/E ratio is -0.31. In terms of profitability, ZYNE's ROE is -0.59%, compared to ACRX's ROE of -0.93%. Regarding short-term risk, ZYNE is less volatile compared to ACRX. This indicates lower risk in terms of short-term price fluctuations for ZYNE.Check ACRX's competition here
Biofrontera Inc. (NASDAQ: BFRIW)
ZYNE vs BFRIW Comparison August 2026
Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZYNE stands at 70.1M. In comparison, BFRIW has a market cap of 13.3M. Regarding current trading prices, ZYNE is priced at $1.30 on the NASDAQ, while BFRIW trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZYNE currently has a P/E ratio of -1.65, whereas BFRIW's P/E ratio is -0.02. In terms of profitability, ZYNE's ROE is -0.59%, compared to BFRIW's ROE of -4.77%. Regarding short-term risk, ZYNE is less volatile compared to BFRIW. This indicates lower risk in terms of short-term price fluctuations for ZYNE.Check BFRIW's competition here
Cosmos Health Inc. (NASDAQ: COSM)
ZYNE vs COSM Comparison August 2026
Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZYNE stands at 70.1M. In comparison, COSM has a market cap of 11.7M. Regarding current trading prices, ZYNE is priced at $1.30 on the NASDAQ, while COSM trades at $0.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZYNE currently has a P/E ratio of -1.65, whereas COSM's P/E ratio is -0.29. In terms of profitability, ZYNE's ROE is -0.59%, compared to COSM's ROE of -0.96%. Regarding short-term risk, ZYNE is more volatile compared to COSM. This indicates higher risk in terms of short-term price fluctuations for ZYNE.Check COSM's competition here
Agile Therapeutics, Inc. (NASDAQ: AGRX)
ZYNE vs AGRX Comparison August 2026
Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZYNE stands at 70.1M. In comparison, AGRX has a market cap of 10.4M. Regarding current trading prices, ZYNE is priced at $1.30 on the NASDAQ, while AGRX trades at $1.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZYNE currently has a P/E ratio of -1.65, whereas AGRX's P/E ratio is -0.89. In terms of profitability, ZYNE's ROE is -0.59%, compared to AGRX's ROE of +1.32%. Regarding short-term risk, ZYNE is more volatile compared to AGRX. This indicates higher risk in terms of short-term price fluctuations for ZYNE.Check AGRX's competition here
Neoleukin Therapeutics, Inc. (NASDAQ: NLTX)
ZYNE vs NLTX Comparison August 2026
Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZYNE stands at 70.1M. In comparison, NLTX has a market cap of 8.2M. Regarding current trading prices, ZYNE is priced at $1.30 on the NASDAQ, while NLTX trades at $3.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZYNE currently has a P/E ratio of -1.65, whereas NLTX's P/E ratio is -0.28. In terms of profitability, ZYNE's ROE is -0.59%, compared to NLTX's ROE of -0.45%. Regarding short-term risk, ZYNE is more volatile compared to NLTX. This indicates higher risk in terms of short-term price fluctuations for ZYNE.Check NLTX's competition here
Lannett Company, Inc. (NYSE: LCI)
ZYNE vs LCI Comparison August 2026
Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZYNE stands at 70.1M. In comparison, LCI has a market cap of 7.4M. Regarding current trading prices, ZYNE is priced at $1.30 on the NASDAQ, while LCI trades at $0.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZYNE currently has a P/E ratio of -1.65, whereas LCI's P/E ratio is -0.04. In terms of profitability, ZYNE's ROE is -0.59%, compared to LCI's ROE of +1.66%. Regarding short-term risk, ZYNE is less volatile compared to LCI. This indicates lower risk in terms of short-term price fluctuations for ZYNE.Check LCI's competition here
Adamis Pharmaceuticals Corporation (NASDAQ: ADMP)
ZYNE vs ADMP Comparison August 2026
Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZYNE stands at 70.1M. In comparison, ADMP has a market cap of 7.3M. Regarding current trading prices, ZYNE is priced at $1.30 on the NASDAQ, while ADMP trades at $0.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZYNE currently has a P/E ratio of -1.65, whereas ADMP's P/E ratio is -0.08. In terms of profitability, ZYNE's ROE is -0.59%, compared to ADMP's ROE of -2.09%. Regarding short-term risk, ZYNE is more volatile compared to ADMP. This indicates higher risk in terms of short-term price fluctuations for ZYNE.Check ADMP's competition here
cbdMD, Inc. (AMEX: YCBD)
ZYNE vs YCBD Comparison August 2026
Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZYNE stands at 70.1M. In comparison, YCBD has a market cap of 6.3M. Regarding current trading prices, ZYNE is priced at $1.30 on the NASDAQ, while YCBD trades at $0.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZYNE currently has a P/E ratio of -1.65, whereas YCBD's P/E ratio is -1.49. In terms of profitability, ZYNE's ROE is -0.59%, compared to YCBD's ROE of -0.34%. Regarding short-term risk, ZYNE is less volatile compared to YCBD. This indicates lower risk in terms of short-term price fluctuations for ZYNE.Check YCBD's competition here
Gelteq Limited Ordinary Shares (NASDAQ: GELS)
ZYNE vs GELS Comparison August 2026
Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZYNE stands at 70.1M. In comparison, GELS has a market cap of 5.2M. Regarding current trading prices, ZYNE is priced at $1.30 on the NASDAQ, while GELS trades at $0.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZYNE currently has a P/E ratio of -1.65, whereas GELS's P/E ratio is -1.14. In terms of profitability, ZYNE's ROE is -0.59%, compared to GELS's ROE of -0.25%. Regarding short-term risk, ZYNE is more volatile compared to GELS. This indicates higher risk in terms of short-term price fluctuations for ZYNE.Check GELS's competition here
Mallinckrodt plc (AMEX: MNK)
ZYNE vs MNK Comparison August 2026
Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZYNE stands at 70.1M. In comparison, MNK has a market cap of 4.5M. Regarding current trading prices, ZYNE is priced at $1.30 on the NASDAQ, while MNK trades at $0.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZYNE currently has a P/E ratio of -1.65, whereas MNK's P/E ratio is -0.44. In terms of profitability, ZYNE's ROE is -0.59%, compared to MNK's ROE of -0.36%. Regarding short-term risk, ZYNE is less volatile compared to MNK. This indicates lower risk in terms of short-term price fluctuations for ZYNE.Check MNK's competition here
Flora Growth Corp. (NASDAQ: FLGC)
ZYNE vs FLGC Comparison August 2026
Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZYNE stands at 70.1M. In comparison, FLGC has a market cap of 4.2M. Regarding current trading prices, ZYNE is priced at $1.30 on the NASDAQ, while FLGC trades at $7.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZYNE currently has a P/E ratio of -1.65, whereas FLGC's P/E ratio is -0.19. In terms of profitability, ZYNE's ROE is -0.59%, compared to FLGC's ROE of -3.03%. Regarding short-term risk, ZYNE is less volatile compared to FLGC. This indicates lower risk in terms of short-term price fluctuations for ZYNE.Check FLGC's competition here
Universe Pharmaceuticals Inc. (NASDAQ: UPC)
ZYNE vs UPC Comparison August 2026
Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZYNE stands at 70.1M. In comparison, UPC has a market cap of 3.8M. Regarding current trading prices, ZYNE is priced at $1.30 on the NASDAQ, while UPC trades at $5.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZYNE currently has a P/E ratio of -1.65, whereas UPC's P/E ratio is -0.75. In terms of profitability, ZYNE's ROE is -0.59%, compared to UPC's ROE of -0.03%. Regarding short-term risk, ZYNE is less volatile compared to UPC. This indicates lower risk in terms of short-term price fluctuations for ZYNE.Check UPC's competition here
Sunshine Biopharma, Inc. (NASDAQ: SBFM)
ZYNE vs SBFM Comparison August 2026
Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZYNE stands at 70.1M. In comparison, SBFM has a market cap of 2.9M. Regarding current trading prices, ZYNE is priced at $1.30 on the NASDAQ, while SBFM trades at $1.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZYNE currently has a P/E ratio of -1.65, whereas SBFM's P/E ratio is -0.20. In terms of profitability, ZYNE's ROE is -0.59%, compared to SBFM's ROE of -0.26%. Regarding short-term risk, ZYNE is more volatile compared to SBFM. This indicates higher risk in terms of short-term price fluctuations for ZYNE.Check SBFM's competition here
PLx Pharma Inc. (NASDAQ: PLXP)
ZYNE vs PLXP Comparison August 2026
Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZYNE stands at 70.1M. In comparison, PLXP has a market cap of 2.5M. Regarding current trading prices, ZYNE is priced at $1.30 on the NASDAQ, while PLXP trades at $0.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZYNE currently has a P/E ratio of -1.65, whereas PLXP's P/E ratio is -0.22. In terms of profitability, ZYNE's ROE is -0.59%, compared to PLXP's ROE of -1.66%. Regarding short-term risk, ZYNE is less volatile compared to PLXP. This indicates lower risk in terms of short-term price fluctuations for ZYNE.Check PLXP's competition here
Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ: SHPH)
ZYNE vs SHPH Comparison August 2026
Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZYNE stands at 70.1M. In comparison, SHPH has a market cap of 2.5M. Regarding current trading prices, ZYNE is priced at $1.30 on the NASDAQ, while SHPH trades at $4.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZYNE currently has a P/E ratio of -1.65, whereas SHPH's P/E ratio is -0.20. In terms of profitability, ZYNE's ROE is -0.59%, compared to SHPH's ROE of -4.08%. Regarding short-term risk, ZYNE is less volatile compared to SHPH. This indicates lower risk in terms of short-term price fluctuations for ZYNE.Check SHPH's competition here
Athenex, Inc. (NASDAQ: ATNX)
ZYNE vs ATNX Comparison August 2026
Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZYNE stands at 70.1M. In comparison, ATNX has a market cap of 2.3M. Regarding current trading prices, ZYNE is priced at $1.30 on the NASDAQ, while ATNX trades at $0.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZYNE currently has a P/E ratio of -1.65, whereas ATNX's P/E ratio is -0.02. In terms of profitability, ZYNE's ROE is -0.59%, compared to ATNX's ROE of +0.22%. Regarding short-term risk, ZYNE is more volatile compared to ATNX. This indicates higher risk in terms of short-term price fluctuations for ZYNE.Check ATNX's competition here
Sonoma Pharmaceuticals, Inc. (NASDAQ: SNOA)
ZYNE vs SNOA Comparison August 2026
Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZYNE stands at 70.1M. In comparison, SNOA has a market cap of 2.3M. Regarding current trading prices, ZYNE is priced at $1.30 on the NASDAQ, while SNOA trades at $1.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZYNE currently has a P/E ratio of -1.65, whereas SNOA's P/E ratio is -1.16. In terms of profitability, ZYNE's ROE is -0.59%, compared to SNOA's ROE of -0.54%. Regarding short-term risk, ZYNE is more volatile compared to SNOA. This indicates higher risk in terms of short-term price fluctuations for ZYNE.Check SNOA's competition here
Procaps Group, S.A. (NASDAQ: PROCW)
ZYNE vs PROCW Comparison August 2026
Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZYNE stands at 70.1M. In comparison, PROCW has a market cap of 2M. Regarding current trading prices, ZYNE is priced at $1.30 on the NASDAQ, while PROCW trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZYNE currently has a P/E ratio of -1.65, whereas PROCW's P/E ratio is N/A. In terms of profitability, ZYNE's ROE is -0.59%, compared to PROCW's ROE of -2.22%. Regarding short-term risk, ZYNE is more volatile compared to PROCW. This indicates higher risk in terms of short-term price fluctuations for ZYNE.Check PROCW's competition here
RedHill Biopharma Ltd. (NASDAQ: RDHL)
ZYNE vs RDHL Comparison August 2026
Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZYNE stands at 70.1M. In comparison, RDHL has a market cap of 1.9M. Regarding current trading prices, ZYNE is priced at $1.30 on the NASDAQ, while RDHL trades at $0.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZYNE currently has a P/E ratio of -1.65, whereas RDHL's P/E ratio is 0.12. In terms of profitability, ZYNE's ROE is -0.59%, compared to RDHL's ROE of +57.40%. Regarding short-term risk, ZYNE is less volatile compared to RDHL. This indicates lower risk in terms of short-term price fluctuations for ZYNE.Check RDHL's competition here
China SXT Pharmaceuticals, Inc. (NASDAQ: SXTC)
ZYNE vs SXTC Comparison August 2026
Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZYNE stands at 70.1M. In comparison, SXTC has a market cap of 1.8M. Regarding current trading prices, ZYNE is priced at $1.30 on the NASDAQ, while SXTC trades at $3.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZYNE currently has a P/E ratio of -1.65, whereas SXTC's P/E ratio is 1.18. In terms of profitability, ZYNE's ROE is -0.59%, compared to SXTC's ROE of -0.31%. Regarding short-term risk, ZYNE is less volatile compared to SXTC. This indicates lower risk in terms of short-term price fluctuations for ZYNE.Check SXTC's competition here
cbdMD, Inc. (AMEX: YCBD-PA)
ZYNE vs YCBD-PA Comparison August 2026
Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZYNE stands at 70.1M. In comparison, YCBD-PA has a market cap of 928.2K. Regarding current trading prices, ZYNE is priced at $1.30 on the NASDAQ, while YCBD-PA trades at $1.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZYNE currently has a P/E ratio of -1.65, whereas YCBD-PA's P/E ratio is -2.69. In terms of profitability, ZYNE's ROE is -0.59%, compared to YCBD-PA's ROE of -0.34%. Regarding short-term risk, ZYNE is less volatile compared to YCBD-PA. This indicates lower risk in terms of short-term price fluctuations for ZYNE.Check YCBD-PA's competition here
Cyclo Therapeutics, Inc. (NASDAQ: CYTHW)
ZYNE vs CYTHW Comparison August 2026
Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZYNE stands at 70.1M. In comparison, CYTHW has a market cap of 928K. Regarding current trading prices, ZYNE is priced at $1.30 on the NASDAQ, while CYTHW trades at $0.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZYNE currently has a P/E ratio of -1.65, whereas CYTHW's P/E ratio is N/A. In terms of profitability, ZYNE's ROE is -0.59%, compared to CYTHW's ROE of -7.30%. Regarding short-term risk, ZYNE is more volatile compared to CYTHW. This indicates higher risk in terms of short-term price fluctuations for ZYNE.Check CYTHW's competition here